Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded. More archive remains to be checked; continue searching. The latest changes are still being indexed. Try again shortly for updated results.
Longeveron said its Phase 2b trial of a stem-cell therapy for a pediatric heart condition failed to meet its primary endpoint, sending shares down about 60% to $2.65 in after-hours trading.
Aeluma reported a $4 million loss in the fourth quarter and lower revenue; shares slid 7.4% to $12.44 in after-hours after a 2.3% close at $13.43.
Down After Hours